Ibio (AMEX:IBIO) Price Movement From Ebola/Enterovirus Hype Ibio (AMEX:IBIO) ($1.47) is a leading provider of plant-based biotechnology for developing and manufacturing biological products. As expected, the hype surrounding the Ebola and Enterorvirus outbreaks in the U.S. will inevitably led to aggressive share price […]
Summary REPR’s flagship product has a firm grip on the growing infusion homecare market and REPR’s stock is trading at a significant discount to what it’s worth. The product is held in high regard by those in the industry, who […]
GeoTeam Looking to Trade Hemispherx Biopharma (HEB) ($0.35) on Chardan Update The Geoteam will look to trade HEB due to Chardan Capital pitching the company as an EBOLA play with a $3 price target. “Chardan Capital affirms its Buy rating […]
Summary We believe Stellar Biotechnologies’ (SBOTF) share price to be a product of a well timed promotional campaign. SBOTF’s share count has risen 88.2% in three short years and the September 2013 PIPE was done at a fully diluted share […]
22nd Century Group, Inc. (XXII) – Closed a $10 million private placement adding to dilution We will look to add to our short position. 22 days after trying to rebut our claims about the company’s share count rising, XXII Closed a $10 […]
China Biologic Products (NASDAQ:CBPO) ($53.09) – a leading fully integrated plasma-based biopharmaceutical company in China, today announced : completed the transaction to acquire an additional 19.84% equity interest in Guizhou Taibang Biological Products Co., Ltd (“Guizhou Taibang”) and increased its […]
Thermal Tennis Inc (OTCCB:TTNS) – CannaSys was originally organized as a Colorado limited liability company in October 2013 and converted to a Colorado corporation in June 2014. Based on their experience for over four years in the medical cannabis dispensary […]
Sciclone Pharmaceuticals (NASDAQ:SCLN)($6.79) – and its partner BTG plc (LSE: BTG), today announced, that the China Food and Drug Administration has approved the registration of DC Bead for the embolization of malignant hypervascularized tumors. BTG and SciClone previously entered into […]